'Neurofit Aqua AD Plus' Receives FDA 510(k) Clearance
Alzheimer's Imaging Analysis Solution
"Neurofit Product Receives Third FDA Clearance"
Neurofit, an artificial intelligence (AI) company specializing in the diagnosis and treatment of brain diseases, announced on February 3 that its brain imaging analysis solution, "Neurofit Aqua AD Plus," which supports the prescription of Alzheimer's disease treatments, has received 510(k) premarket notification clearance from the U.S. Food and Drug Administration (FDA).
With this approval, Neurofit has secured its third FDA clearance, following its neurodegeneration imaging analysis software "Neurofit Aqua" and its positron emission tomography (PET) image quantification software "Neurofit Scale PET."
Neurofit Aqua AD Plus is an integrated solution that provides the brain imaging analysis functions required for prescribing Alzheimer's disease treatments. By quantitatively analyzing magnetic resonance imaging (MRI) and PET images, it supports clinical decision-making throughout the treatment cycle?from determining eligibility for prescription before drug administration, to monitoring side effects during administration, and evaluating treatment efficacy after administration.
The newly FDA-approved product is an advanced version of the existing "Neurofit Aqua AD." Through AI-based brain MRI analysis, it automatically analyzes the location and number of low-intensity lesions associated with cerebral microbleeds and superficial siderosis, as well as high-intensity lesions related to brain edema. This enables a more precise assessment of risk factors associated with anti-amyloid antibody therapies.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Bin Joongil, Co-CEO of Neurofit, stated, "With this FDA approval, we can now actively introduce Neurofit's imaging analysis technology to the U.S. market for Alzheimer's disease treatment," adding, "We plan to strengthen our global business by expanding collaborations with medical institutions in North America."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.